Treatment Options to Consider

Slides:



Advertisements
Similar presentations
Www. Clinical trial results.org Unfractionated heparin 60 U/kg bolus, then 12 U/kg per hour adjusted to an activated partial thromboplastin time of 50.
Advertisements

Adjunctive Antithrombotic for PCI Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville.
Addressing the Challenges in Primary and Secondary Stroke Prevention
SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.
CLINICAL DILEMMAS IN HEART FAILURE:
Learning Objectives. Learning Objectives Variable Response to Clopidogrel.
Preventing Thrombotic Complications in ACS: State of the Art
Acute Hypertension Management Optimizing Door-to-Needle Time in Ischemic Stroke.
Oral Anticoagulation and Preventing Stent Thrombosis
New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.
Anticoagulants in Interventional Cardiology:
The Role of Anticholinergic Therapy in Moderate to Severe Asthma
Updates in Anticoagulation: What Did We Learn From ESC 2017?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
A CASE CHALLENGE IN HFrEF:
The Nurse View.
A New Era for NOACs:.
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Unmet Needs in the Secondary Prevention in ACS
It’s Elementary.
New Perspectives in CAD and PAD: Weighing the Latest Evidence
Selecting NOACs for High-Risk Patients
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
Heart Failure Prevention: Mission Impossible?
The Essentials for Secondary Stroke Prevention
Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.
A Unified Approach to Anticoagulant Therapy in ACS: What's Missing?
Treating HFrEF: Challenges Faced
NOACS: Emerging data in ACS/IHD
CV Risk Doesn't End in the Cath Lab
AF and PCI in Practice.
Antithrombotic Protection in CAD and HF
Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.
Five Things You Need to Know About Secondary Prevention Post-ACS
CV Risk Doesn't End in the Cath Lab
Anticoagulation and Thrombosis Management
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
The European Society of Cardiology Presented by RJ De Winter
Challenging the Myths in Heart Failure With Reduced Ejection Fraction
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Factor Xa Inhibitors in PAD
CAD/PAD in Primary Care
Cancer-Associated Thrombosis
CAD and HF Often Coexist
A Case Challenge.
Early Management of NSTE-ACS: From the ED to the Cath Lab
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Antithrombotic Therapy in Vascular Protection: From CAD to HF
Updates in Anticoagulation: Key Sessions at ESC 2017
Iron Deficiency in Heart Failure
A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.
Antithrombotics in Arterial Disease: Focus on Coronary Disease
NOACs in CAD.
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
Factor Xa Inhibitors in Coronary Artery Disease
Improving Adherence to Antiplatelet Therapy After an ACS Event
Program Goal. Program Goal Disclaimer Overview.
Cardiology Fellow X Factor: An ACS Case of Therapeutic Challenges
Disease Burden of VTE Phases of VTE Treatment.
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Uptitration of Medications in HF: Start Low but Aim High and Stay High
ESC Guideline on the Management of STEMI Recommendation for DAPT
My PAH Patient.
Top Tips in Evidence-Based Care for HFrEF
Key Data on Improving Outcomes in HF Patients
Antithrombotic Therapy in AF Patients Undergoing PCI
What's New in NOACs in AF?.
Treating Pulmonary Embolism Today
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

Improving Outcomes in a Recent ACS Part 1: Anticoagulation in a STEMI Patient

Treatment Options to Consider

ATOLL: IV Enoxaparin in Primary PCI:

ATOLL: Results

ESC Guidelines: Periprocedural Anticoagulant Medication in Primary PCI

ACCF/AHA Guidelines: Adjunctive Anticoagulant Therapy in Primary PCI

Rivaroxaban: ATLAS ACS 2-TIMI 51: Study Design

ATLAS ACS 2-TIMI 51: Mortality Benefit With Very Low-Dose Rivaroxaban in STEMI Patients

Otamixaban: TAO Study Design

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)